Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) changed by 0.00% from its latest closing price compared to the recent 1-year high of $100.00. The company’s stock price has collected 3.37% of gains in the last five trading sessions. Press Release reported on 10/28/20 that Ultragenyx Announces Pricing of Public Offering of Common Stock
Is It Worth Investing in Ultragenyx Pharmaceutical Inc. (NASDAQ :RARE) Right Now?
Plus, the 36-month beta value for RARE is at 2.27. Opinions of the stock are interesting as 12 analysts out of 17 who provided ratings for Ultragenyx Pharmaceutical Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $102.59, which is -$7.56 below the current price. RARE currently public float of 56.95M and currently shorts hold a 12.31% ratio of that float. Today, the average trading volume of RARE was 341.49K shares.
RARE’s Market Performance
RARE stocks went up by 3.37% for the week, with a monthly jump of 15.59% and a quarterly performance of 21.55%, while its annual performance rate touched 135.73%. The volatility ratio for the week stands at 7.41% while the volatility levels for the past 30 days are set at 5.62% for Ultragenyx Pharmaceutical Inc.. The simple moving average for the period of the last 20 days is 3.17% for RARE stocks with a simple moving average of 34.76% for the last 200 days.
Analysts’ Opinion of RARE
Many brokerage firms have already submitted their reports for RARE stocks, with Wedbush repeating the rating for RARE by listing it as a “Outperform.” The predicted price for RARE in the upcoming period, according to Wedbush is $75 based on the research report published on August 02nd of the previous year 2019.
Morgan Stanley, on the other hand, stated in their research note that they expect to see RARE reach a price target of $83, previously predicting the price at $68. The rating they have provided for RARE stocks is “Overweight” according to the report published on March 27th, 2019.
Raymond James gave a rating of “Outperform” to RARE, setting the target price at $80 in the report published on February 22nd of the previous year.
RARE Trading at 10.63% from the 50-Day Moving Average
After a stumble in the market that brought RARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.00% of loss for the given period.
Volatility was left at 5.62%, however, over the last 30 days, the volatility rate increased by 7.41%, as shares surge +10.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.03% upper at present.
During the last 5 trading sessions, RARE rose by +3.37%, which changed the moving average for the period of 200-days by +55.76% in comparison to the 20-day moving average, which settled at $92.54. In addition, Ultragenyx Pharmaceutical Inc. saw 122.43% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at RARE starting from Bedrosian Camille L, who sale 262 shares at the price of $88.00 back on Oct 14. After this action, Bedrosian Camille L now owns 35,789 shares of Ultragenyx Pharmaceutical Inc., valued at $23,056 using the latest closing price.
Parschauer Karah Herdman, the EVP and General Counsel of Ultragenyx Pharmaceutical Inc., sale 325 shares at $88.00 during a trade that took place back on Oct 14, which means that Parschauer Karah Herdman is holding 23,968 shares at $28,600 based on the most recent closing price.
Stock Fundamentals for RARE
Current profitability levels for the company are sitting at:
- -408.98 for the present operating margin
- +83.08 for the gross margin
The net margin for Ultragenyx Pharmaceutical Inc. stands at -388.31. The total capital return value is set at -52.53, while invested capital returns managed to touch -50.10. Equity return is now at value -44.80, with -26.30 for asset returns.
Based on Ultragenyx Pharmaceutical Inc. (RARE), the company’s capital structure generated 53.90 points at debt to equity in total, while total debt to capital is 35.02. Total debt to assets is 30.82, with long-term debt to equity ratio resting at 52.79. Finally, the long-term debt to capital ratio is 34.30.
When we switch over and look at the enterrpise to sales, we see a ratio of 19.41, with the company’s debt to enterprise value settled at 0.18. The receivables turnover for the company is 4.55 and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.24.
Jeff Brown has made some incredible revelations before… The angel investor predicted the top tech stock on the S&P 500 in three of the last four years…
He unveiled the key piece inside Apple’s new iPhone – on stage in New Haven, CT – months before the phone has even hit the market.